Lecture 55: Introduction to Oncology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/50

encourage image

There's no tags or description

Looks like no tags are added yet.

51 Terms

1
New cards

cancer is a condition characterized by

the uncontrolled growth and proliferation of cells

2
New cards

what is the number one cause of death for veterinary patients?

cancer

3
New cards

causes of cancer include

  • genetics

  • environment

  • infectious

  • dietary

  • hormonal

  • chronic inflammation/trauma


4
New cards

heritable cancers in dogs

  • GSD → RCND

  • bernese mountain dogs → histiocytic sarcoma

  • scottish deerhound → osteosarcoma

  • goldens → hemangiosarcoma

  • shelties, scotties, westies, beagles, yorkies → TCC
    many breeds → lymphoma


5
New cards

environmental factors that can cause cancer

  • tobacco smoke

  • pesticides, herbicides, and insecticides → TCC in dogs

  • living environment → lymphoma

  • sunlight → HSA and SCC

  • radiation → SCC and OSA

  • asbestos → mesothelioma


6
New cards
<p>what is this?</p>

what is this?

hemangiosarcoma

7
New cards
<p>what is this?</p>

what is this?

squamous cell carcinoma

8
New cards

tobacco smoke

  • humans → 30% of deaths in USA

  • dogs → 3.4 fold increased risk (lymphoma, nasal carcinomas)

  • cats → 2.4 fold increased risk (lymphoma, oral SCC)


9
New cards

pesticides, herbicides, insecticides

  • 2,4-D dichlorophenoxyacetic acid pesticides → lymphoma in humasn and dogs

  • 2,4-D and 4-chloro-2-methylphenoxy acetic acid → TCC of the bladder in dogs


10
New cards

FeLV

  • 60 fold increased risk for lymphoma

  • insertional mutagenesis


11
New cards

FIV

4 fold increased risk for lymphoma

12
New cards

FeLV/FIV co-infection

  • synergistic risk

  • 80 fold increased risk for lymphoma


13
New cards

spirocerca lupi

esophageal fibrosarcoma

14
New cards

schistosomiasis

bladder cancer

15
New cards

FeSV

multifocal sarcomas

16
New cards

papillomavirus

cutaneous warts

17
New cards

marek’s disease

herpes virus and lymphoma

18
New cards

bovine leukemia virus =

lymphoma

19
New cards

hormonal factors

  • sex hormones in females

  • mammary cancer in dogs and cats → intact female dogs 7x increased risk

  • cats → aggressive, often rapidly fatal disease

  • spaying before 6 months


20
New cards

trauma/chronic inflammation

  • may lead to malignant transformation

  • feline ocular sarcoma

  • feline injection site sarcoma

  • IBD


21
New cards

appropriate treatment or combination of treatments is determined by

tumor stage, tumor type, other factors like owner finances, capabilities, etc

22
New cards

what are the 3 main therapeutic modalities?

  • divided into local vs systemic

  • local therapies → surgery, radiation

  • systemic therapies → chemotherapy


23
New cards

tumor stage often dictates appropriate treatment like

bulky disease treated by local therapy such as surgery

24
New cards

tumor behavior determines

appropriate treatment → infiltrative growth, metastatic rate

25
New cards

surgery for cancer

  • best cancer control with exceptions → lymphoproliferative diseases, metastatic diseases

  • can be diagnostic or therapeutic


26
New cards

what is the main indication for surgery for cancer?

solid (localized) tumors

27
New cards

limitations of surgery for cancer

patient health, cost, morbidity/mortality, systemic or advanced tumors

28
New cards

toxicity from surgery

infection, incomplete resection, dehiscence, tumor seeding

29
New cards

radiation therapy

  • utilizes ionizing radiation to destroy tumor cells

  • used to treat small amounts of residual tumor cells

  • can also be used to reduce pain symptoms

  • limitations → cost, availability, localized lesions


30
New cards

chemotherapy

  • involves use of cytotoxic drugs with narrow therapeutic indices to treat primary tumors, prevent/treat metastatic lesions, palliate tumor-related symptoms

  • targeted drugs are becoming more common

  • treatment can be used as → sole modality, additive therapy, palliative therapy


31
New cards

induction chemotherapy

using chemo as a sole therapy to treat primary tumors

32
New cards

indications for induction chemotherapy

  • chemosensitive tumors → LSA, plasmacytomas, TVT

  • palliation

  • intralesional


33
New cards

adjuvant

adding chemotherapy to some other regimen such as following surgery or FT for tumors with high metastatic rates

34
New cards

indications for adjuvant chemo

  • additional local control

  • intralesional

  • metastatic tumors

  • palliation


35
New cards

neoadjuvant

using chemotherapy in hopes of downstaging tumors prior to surgery or other regimens

36
New cards

indications for neoadjuvant therapy

  • surgery not feasible

  • investigational drugs

  • test dose


37
New cards

photodynamic therapy

administration and activation of photoactive agent

38
New cards

cryotherapy

local therapy for select superficial tumors

39
New cards

hyperthermia

local therapy typically combined with surgery or radiation

40
New cards

immunotherapy

systemic therapy for select tumors

41
New cards

definitive therapy

  • desired goal is long-term control

  • more expensive, higher morbidity


42
New cards

palliative therapy

  • desired goal is the reduction of tumor-related symptoms

  • less expensive, lower morbidity


43
New cards

median survivial time

  • point of time at which 50% of patients have succumbed d/t cancer

  • assumes normal distribution


44
New cards

disease-free interval

length of time from disease resolution to recurrence of death from disease

45
New cards

cure

control such that DFI >3 years

46
New cards

complete response to therapy

  • cure → complete disappearance of cancer, patient has normal life expectancy

  • complete remission → complete disappearance of cancer for a minimum of 2 dosing intervals


47
New cards

partial response to therapy

partial remission → 30-50% or greater decrease in tumor burden and no new disease for a minimum of 2 dosing intervals

48
New cards

overall response rate =

CR + PR

49
New cards

stable disease

<50% decrease and no more than a 25% increase in tumor burden for a minimum of 2 dosing intervals

50
New cards

progressive disease

25% increase in tumor burden and/or the development of new lesions (in spite of therapy)

51
New cards

palliative responses to therapy

  • improved quality of life

  • measured using performance scale in humans

  • decreased symptom-ology

  • increased well being

  • dose not directly equate with improved survival